Auteurs

Adrian Toutoungi

Associé

Read More

Alison Dennis

Associé

Read More

Colin McCall

Associé

Read More
Auteurs

Adrian Toutoungi

Associé

Read More

Alison Dennis

Associé

Read More

Colin McCall

Associé

Read More

4 février 2021

Edison Open House Global Healthcare 2021 – key takeaways from our panel

  • Quick read

Last week, we partnered with Edison Group and the London Stock Exchange to host the Edison Open House Global Healthcare 2021 virtual conference. During the event, partners Adrian Toutoungi, Alison Dennis and Colin McCall led a workshop panel which covered negotiating partnering deals with Big Pharma.

Over the course of the panel, representatives from among the conference's 35 hand-picked life sciences companies and investors shared their views on a range of partnering issues, including current trends, the impact of COVID-19, and deal-making in a virtual environment.

Top insights from the workshop session

  • 2020 was a boom year for biopharma partnering, with over 62 deals valued at $50 million+ (aggregate upfronts and milestones). The average deal size was $1.2 billion, which is the largest we've seen for at least 10 years. 
  • China regional deals – current PRC practices regarding forced technology transfer (including local clinical trials, local manufacturing and disclosure of manufacturing techniques) can be a deal-breaker for licensors with valuable manufacturing process know-how but are not a problem in many deals. 
  • The meteoric rise of Chinese biopharma companies continues, with increasing numbers of out-licensing deals in relation to Chinese-developed assets in 2020.
  • Given the long-term nature of partnering deals and the dynamic nature of M&A activity in the biotech sector, careful thought is needed when future-proofing deals so that you can handle new parties becoming involved. Assignment and change of control clauses require close attention, as do firewalls.
  • Negotiating reversion rights in the event of early termination, and how to value the work done by the licensee during the deal, requires strong consideration and can be a difficult issue in the optimistic early stages of a relationship; the group discussed a variety of approaches to this.
  • Withholding tax continues to be a potential pitfall – even for experienced dealmakers. Paying particular attention to the tax treatment of the upfronts, milestones and royalty payments in the drafting (which are definitely not boilerplate clauses) and seeking local tax advice in all relevant jurisdictions on a substantial deal is highly recommended.

Find out more

To discuss any of the issues raised in this article in more detail, please reach to a member of our Life Sciences & Healthcare team.

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

pipette
Synapse

Private equity investment in life sciences sector

30 juillet 2020
IN-DEPTH ANALYSIS

par plusieurs auteurs

Cliquer ici pour en savoir plus
scientist-with-molecule-models
Sciences de la vie et Santé

Impact of COVID-19 on venture-backed biotech companies – Part 2: Investment and cash flow

23 juin 2020
IN-DEPTH ANALYSIS

par Adrian Toutoungi et Josef Fuss

Cliquer ici pour en savoir plus
scientist-with-vials
Sciences de la vie et Santé

Impact of COVID-19 on venture-backed biotech companies – Part 1: Operational issues

22 juin 2020
IN-DEPTH ANALYSIS

par Adrian Toutoungi et Josef Fuss

Cliquer ici pour en savoir plus